Thyrocare Technologies Ltd
P&L
Quarterly Consolidated
vs Q1 FY26
Thyrocare Technologies Reports 22% YoY Revenue Growth in Q2FY26, Declares Interim Dividend and Bonus Shares
14 Oct 2025 · 14 Oct 2025, 04:42 pm
Summary
Thyrocare Technologies Limited, a leading healthcare diagnostics company, has announced their results for the quarter ended September 30, 2025. The company reported a 22% YoY growth in revenue, with a Normalized EBITDA and PAT of INR 75.36 Cr and INR 47.90 Cr respectively. The company also declared an interim dividend of INR 7 per equity share and approved a bonus issue in the proportion of 2:1.
Key Highlights
- 1
Consolidated revenue registered a 22% year-on-year growth, driven primarily by a 24% increase in the Pathology segment
- 2
In the Pathology business, franchise revenue grew by 20% year-on-year, while partnership revenue recorded a robust 35% year-on-year growth
- 3
Thyrocare, India’s largest diagnostic test volume processor, processed 53.3 million tests in Q2FY26, marking a strong 21% year-on-year growth
- 4
Consolidated Gross Margin stood at 72%, while the EBITDA stands at 33%
- 5
Consolidated EBITDA grew by 48% year-on-year, and Profit After Tax (PAT) grew by 82% year-on-year
- 6
The company is debt-free on a consolidated basis and holds a net cash and cash equivalents including short-term investments of over INR 190 crores
- 7
Four new laboratories were added in Vijayawada, Bhagalpur, Roorkee, and Kashmir during H1FY26
Management Comments
Rahul Guha
MD & CEO, Thyrocare Technologies Ltd
We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India
Alok Kumar Jagnani Group CFO
We are delighted with Thyrocare’s strong Q2FY26 performance, which reflects the strength of our business fundamentals, disciplined financial management, and the unwavering commitment of our teams. As we mark 25 years of trust and innovation, the bonus share announcement underscores our commitment to our shareholders and investors, and reinforces confidence in our long-term growth journey
Informational and educational content only. Not investment advice.